Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter January 14, 2015

Evaluation of fetuin-A and carotid intima-media thickness in adolescent type 1 diabetic patients

Soha M. Abd El Dayem, Ahmed A. Battah, Abo El Magd El Bohy and Amal El Shehaby

Abstract

Objective: To evaluate fetuin-A level and carotid intima-media thickness (CIMT) in adolescent type 1 diabetics.

Patients and methods: The study included 62 type 1 diabetic patients and 30 healthy volunteers of the same age and sex. Blood sample was taken for assessment of glycosylated hemoglobin (HbA1), lipid profile, and fetuin-A. Urine sample was also taken for assessment of albumin/creatinine ratio. Anthropometric measurements were taken, including weight, height, and waist and hip circumference. CIMT was assessed for all patients and controls.

Results: Serum fetuin-A, Rt., Lt. and both CIMT were significantly higher in diabetics. Fetuin-A had a significant positive correlation with duration of disease, waist and hip circumference, BMI, BMI SDS, waist/height ratio, Rt., Lt. and both CIMT. Stepwise multiple regression analysis revealed that the duration of disease, waist/height ratio, and HDL-c were the factors related to fetuin-A.

Conclusion: Adolescent type 1 diabetic patients have high fetuin-A levels and increased CIMT, with the latter representing the development of early atherosclerosis. In this light, adolescents with type 1 diabetes require frequent follow up for early detection of atherosclerosis.


Corresponding author: Soha M. Abd El Dayem, Professor of Pediatrics, Consultant of Diabetes and Endocrinology, National Research Centre, Medical Research Division, Pediatrics Department, Cairo, Egypt, Phone: +2 01006716852, E-mail:

References

1. Pedersen KO. Fetuin, a new globulin isolated from serum. Nature 1944;154:575–6.10.1038/154575a0Search in Google Scholar

2. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357–66.10.1172/JCI17202Search in Google Scholar PubMed PubMed Central

3. Merx MW, Schäfer C, Westenfeld R, Brandenburg V, Hidajat S, et al. Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol 2005;16:3357–64.10.1681/ASN.2005040365Search in Google Scholar PubMed

4. Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, et al. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabol Clin Exp 2010;59:873–8.10.1016/j.metabol.2009.10.005Search in Google Scholar PubMed

5. Mori K, Emoto M, Araki T, Yokoyama H, Lee E, et al. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism 2008;57:1248–52.10.1016/j.metabol.2008.04.019Search in Google Scholar PubMed

6. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, et al. Alpha2-Heremans–Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006;29:853–7.10.2337/diacare.29.04.06.dc05-1938Search in Google Scholar PubMed

7. Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and non diabetic subjects. Diabetes Care 2006;29:468.10.2337/diacare.29.02.06.dc05-1484Search in Google Scholar PubMed

8. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, et al. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006;113:1760–7.10.1161/CIRCULATIONAHA.105.588723Search in Google Scholar PubMed PubMed Central

9. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, et al. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008;118:2555–62.10.1161/CIRCULATIONAHA.108.814418Search in Google Scholar PubMed

10. Rittig K, Thamer C, Haupt A, Machann J, Peter A, et al. High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis 2009;207:341–2.10.1016/j.atherosclerosis.2009.05.018Search in Google Scholar PubMed

11. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 1989;58:631–40.10.1016/0092-8674(89)90098-6Search in Google Scholar

12. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 2008;12:3:e1765. doi: 10.1371/journal.pone.0001765.10.1371/journal.pone.0001765Search in Google Scholar

13. Fiore CE, Celotta G, Politi GG, Di Pino L, Castelli Z, et al. Association of high alpha2- Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 2007;195:110–5.10.1016/j.atherosclerosis.2006.08.052Search in Google Scholar

14. Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, et al. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) 2007;66:246–50.10.1111/j.1365-2265.2006.02716.xSearch in Google Scholar

15. Tanner JM, Hiernaux J, Jarman S. Growth and physical studies. In: Weiner JS, Lourie JA, editors. Human biology: a guide to field methods. Oxford: Blackwell Scientific Publishers, 1969:3–41.Search in Google Scholar

16. Cameron N. The methods of auxological anthropology. In: Falkner F, Tanner JM, editors. Human growth 3 methodology. New York: Plenum Press, 1986:3–46.Search in Google Scholar

17. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459–67.10.1161/CIRCULATIONAHA.106.628875Search in Google Scholar

18. Järvisalo MJ, Raitakari M, Toikka JO, Putto-Laurila A, Rontu R, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation 2004;109:1750–5. [Abstract/Free Full Text].10.1161/01.CIR.0000124725.46165.2CSearch in Google Scholar

19. Singh TP, Groehn H, Kazmers A. Vascular function and carotid intimal medial thickness in children with insulin-dependent diabetes mellitus. J Am Coll Cardiol 2003;41:661–5.10.1016/S0735-1097(02)02894-2Search in Google Scholar

20. Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, et al. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab 2010;95:4877–81.10.1210/jc.2010-0148Search in Google Scholar PubMed

21. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 2008;93:4479–85.10.1210/jc.2008-1505Search in Google Scholar PubMed

22. Ramadan A, Shoukry A, Ismail MI, Borai M. Serum fetuin-A levels in type 2 diabetes patients with early diabetic nephropathy: it’s relation to diabetes control. J Am Sci 2011;7:759–65.Search in Google Scholar

23. Kilian Rittig A, Thamera C, Haupta A, Machann J, Peter A, et al. High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis 2009;207:341–2.10.1016/j.atherosclerosis.2009.05.018Search in Google Scholar PubMed

24. Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 2006;29:468.10.2337/diacare.29.02.06.dc05-1484Search in Google Scholar PubMed

25. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005;67:1070–7.10.1111/j.1523-1755.2005.00172.xSearch in Google Scholar PubMed

26. Roos M, Lutz J, Salmhofer H, Luppa P, Knauss A, et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf) 2008;68:660–5.10.1111/j.1365-2265.2007.03074.xSearch in Google Scholar PubMed

27. Lehtinen AB, Burdon KP, Lewis JP, Langefeld CD, Ziegler JT, et al. Association of alpha2- Heremans-Schmid glycoprotein polymorphisms with subclinical atherosclerosis. J Clin Endocrinol Metab 2007;92:345–52.10.1210/jc.2006-0429Search in Google Scholar PubMed

28. Stein EA. Statins and children: whom do we treat and when? Circulation 2007;116:594–5.10.1161/CIRCULATIONAHA.107.717777Search in Google Scholar PubMed

29. Haller MJ, Stein JM, Shuster JJ, Theriaque D, Samyn MM, et al. Atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009;22:65–8.10.1515/JPEM.2009.22.1.65Search in Google Scholar

Received: 2014-7-5
Accepted: 2014-11-14
Published Online: 2015-1-14
Published in Print: 2015-3-1

©2015 by De Gruyter